FILING ANALYSIS · FRIDAY, NOVEMBER 6
Aligos Therapeutics, Inc. ALGS — 8-K: Results of Operations and Financial Condition
neutral
Aligos Therapeutics' Q3 2026 financial results show a net loss of $21.9 million and cash reserves of $31.1 million, expected to fund operations into Q1 2027. The company's pipeline progress, including the Phase 2 B-SUPREME study of pevifoscorvir sodium, is on track but lacks quantified surprises to drive a significant stock move.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →